close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oligomerix, Inc.

News headline image
Oligomerix Completes Ph 1a Clinical Study on OLX-07010
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Elects New Chairman William Caple to Board of Directors
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Published Results from a Preclinical Therapeutic Treatment Study on an Oral Experimental Drug in Development for Alzheimer’s and Rare Neurodegenerative Diseases
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease and Rare Neurodegenerative Diseases
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer's Disease (CTAD) and Neuroscience 2022 Meetings
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer's Disease (CTAD) Conference and Society for Neuroscience Meeting
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Announces Late-Breaking Presentation at 2021 Clinical Trials on Alzheimer's Disease (CTAD) Conference
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix to Present at Alzheimer's Association International Conference
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix Appoints Chief Medical Officer William Erhardt, M.D., to Board of Directors
From Oligomerix, Inc.
Via Business Wire
News headline image
Oligomerix to Participate in Upcoming Life Sciences Conferences
From Oligomerix, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today